Tulisokibart (MK-7240) - (ATLAS-UC)

June 22, 2026: Merck (NYSE: MRK) reported positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) of tulisokibart (MK-7240), an investigational humanized anti-TL1A monoclonal antibody, in adults with moderately to severely active ulcerative colitis. The trial met its primary endpoint: clinical remission per Modified Mayo Score at week 12, and also met key secondary endpoints. Merck said the safety profile was consistent with prior Phase 2 studies, with no safety concerns identified.

Merck plans to present Study 2 results together with data from the ongoing ATLAS-UC Study 1 (induction + maintenance) at an upcoming scientific congress and to share results with regulatory authorities.

Development status: tulisokibart is being evaluated across seven indications. Phase 3 programs include ATLAS-UC (NCT06052059) in ulcerative colitis and ARES-CD (NCT06430801) in Crohn’s disease. Phase 2 studies are ongoing in SSc-ILD (NCT05270668), rheumatoid arthritis (NCT07176390), psoriatic arthritis (NCT07486960), radiographic axial spondyloarthritis (NCT07133633), and hidradenitis suppurativa (NCT06956235).